Tools


Home > Research > Integrative Biomedical Informatics


Integrative Biomedical Informatics

Mission & Research lines

The huge wealth of biomedical information that is currently available is underused because the difficulties in seeking, integrating, analysing the relevant one. There is also a great difficulty for the identification and use of clinically actionable information. The goal of the Integrative Biomedical Informatics (IBI) group, led by Laura I. Furlong and Ferran Sanz, is to develop computational methods and tools to address these challenges, with the aim of better understanding human health and disease and contributing to the design of more effective and safe therapeutic interventions.

This group promotes and tackles synergistic and integrative strategies for affording biomedical problems, making use of approaches developed within the IBI group but also fostering the collaboration between research groups of the GRIB.

The ongoing research lines of the IBI group are:

  • New methods and tools for knowledge extraction and linkage from biomedical literature and other publicly available sources.
  • Development of strategies for the research reuse of clinical data
  • Network biology for the study of human diseases and drug toxicity.
  • Integrative knowledge management and exploitation in drug discovery and development.

The group is currently coordinating two large scale scientific initiatives:

  • The IMI project eTOX that integrates bioinformatics and chemoinformatics approaches for the development of expert systems allowing the in silico prediction of drug toxicity.
  • The H2020 project MedBioinformatics on the translational and clinical application of bioinformatics.

The group is also partner in other EU-funded projects, like the ongoing IMI projects:

  • Open PHACTS which aim is to develop an open access innovation platform, called Open Pharmacological Space (OPS), via a semantic web approach.
  • EMIF, dealing with the creation and exploitation of a European Medical Informatics Framework.
  • iPiE, aiming to develop a predictive framework for the environmental impact of drugs.

And the ongoing H2020 projects:

  • EU-ToxRisk, aiming to achieve a paradigm shift in toxicology towards a more efficient and animal-free chemical safety assessment.
  • ELIXIR-EXCELERATE, to accelerate the implementation of Europe's life-science data infrastructure.

Other examples of recent European projects participated or coordinated by the IBI group are INBIOMEDvisionVirtual Physiological Human NOEEU-ADR@neurIST and CancerGRID.



Site Information